SEC Tracker
Get the app

Femasys FEMY

Femasys FY 2023: revenue $1.1M, down 11%; diluted EPS −$18.60

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Femasys reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$1.1M−11% from $1.2M in FY 202210-K income statement, on EDGAR
  2. Net income−$14.2MAgainst −$11.4M in FY 202210-K income statement, on EDGAR
  3. Diluted EPS−$18.60Against −$19.20 in FY 2022. Split-adjusted, as the tables show it; the filing reported −$0.9310-K income statement, on EDGAR
  4. Cash and cash equivalents$21.7M+68% from $13.0M in FY 202210-K balance sheet, on EDGAR
  5. Cash from operations−$11.3MAgainst −$10.7M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Femasys files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. DarioHealth DRIO public float $28M, Jun 30, 2025
  2. Cerenome CNSY public float $32M, Jun 30, 2025
  3. electroCore ECOR public float $28M, Jun 30, 2025
  4. QT Imaging Holdings QTI public float $33M, Jun 30, 2025
  5. Nephros NEPH public float $27M, Jun 30, 2025